The Dermatology Digest
DECEMBER 24, 2024
Raj Chovatiya, MD, PhD, Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago, IL, reviews the latest efficacy and safety data on oral and topical Janus kinase (JAK) inhibitors used in dermatology. He spoke on this topic at the 2024 Revolutionizing Atopic Dermatitis (RAD) Conference.
The Dermatology Digest
DECEMBER 6, 2024
Artificial intelligence (AI), augmented reality, social media, telehealth, and other emerging technologies are changing the way that healthcare is delivered, and cosmetic dermatology is no exception. She believes some conditions, consultations, and procedures require in-person appointments to ensure safety and accuracy.
Dermatology Times
FEBRUARY 19, 2024
Katherine Economy, MD, discusses the challenges and opportunities of treating pregnant patients with dermatologic conditions, emphasizing the importance of comprehensive medication reviews, patient-centered decision-making, and the need for including pregnant patients in clinical trials.
Dermatology Times
SEPTEMBER 26, 2023
Ruth Ann Vleugels, MD, and Christopher Bunick, MD, agreed that the long-term safety data for JAK inhibitors makes them preferable to systemic steroids.
The Dermatology Digest
FEBRUARY 8, 2024
The Dermatology Digest asked key thought leaders and editorial advisory board members to take out their crystal balls and weigh in on what’s to come in 2024 and beyond. It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.” We will, for sure, have new medications for chronic urticaria.”
Dermatology Times
MAY 16, 2024
Bristol Myers Squibb announced 70% of patients maintained significant improvement after 4 years with no new safety concerns.
Dermatology Times
OCTOBER 1, 2024
After releasing promising data from several clinical trials, Burnett discussed the importance of studying efficacy and safety across diverse populations.
Expert insights. Personalized for you.
74 
Let's personalize your content